

[Dihydroartemisinin + piperazine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

ATC codes: [P01BF05](#)

EMLc

Indication

Malaria due to Plasmodium falciparum ICD11 code: [1F40](#)

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc)

Oral > Solid > tablet: 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Dihydroartemisinin + piperazine](#)

DrugBank

[Artemimol](#),

[Piperaquine](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of piperazine in the formulation description instead of the medicine name.